

# Once Daily Etravirine versus Efavirenz in Treatment-Naive **SENSE Trial**

# Once Daily Etravirine *versus* Efavirenz in Treatment-Naive SENSE: Study Design

## Study Design: SENSE Study

- **Background:** Randomized, controlled, double-blind, phase 2 trial evaluating efficacy of once-daily etravirine compared with efavirenz in treatment-naïve persons with HIV
- **Inclusion Criteria (n = 157)**
  - Age ≥18 years
  - Antiretroviral-naïve
  - HIV RNA >5000 copies/mL
  - No resistance to study drugs
- **Treatment Arms**
  - ETR 400 mg daily + 2NRTIs\*
  - Efavirenz 600 mg daily + 2NRTIs\*

\*NRTIs = tenofovir DF-emtricitabine, abacavir, lamivudine, or zidovudine-lamivudine

**Etravirine 400 mg once daily  
+ 2 NRTIs**  
(n = 79)

**Efavirenz 600 mg once daily  
+ 2 NRTIs**  
(n = 78)


SENSE = **S**tudy of **E**favirenz **N**europsychiatric events **versuS** **E**travirine

**Source:** Gazzard B, et al. *AIDS*. 2011;25:2249-58.

# Once Daily Etravirine *versus* Efavirenz

## SENSE: Results

Week 48: Virologic Response (ITT-TLOVR\*)




\*ITT-TLOVR = Intention to Treat-Time to Loss of Virologic Response

Source: Gazzard B, et al. AIDS. 2011;25:2249-58.

# Once Daily Etravirine *versus* Efavirenz

## SENSE: Result



# Once Daily Etravirine *versus* Efavirenz

## SENSE: Conclusions

**Conclusion:** “First-line treatment with etravirine 400mg once daily and two nucleoside reverse transcriptase inhibitors (NRTIs) led to similar rates of HIV RNA suppression, compared with efavirenz and two NRTIs. None of the patients with virological failure in the etravirine arm developed resistance to nonnucleosides.”

# Acknowledgment

The **National HIV Curriculum** is an AIDS Education and Training Center (AETC) Program supported by the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) as part of an award totaling \$800,000 with 0% financed with non-governmental sources. This project is led by the University of Washington's Infectious Diseases Education and Assessment (IDEA) Program.

*The content in this presentation are those of the author(s) and do not necessarily represent the official views of, nor an endorsement, by HRSA, HHS, or the U.S. Government.*

